Symbols / VERA
VERA Chart
About
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.00B |
| Enterprise Value | 2.29B | Income | -251.94M | Sales | — |
| Book/sh | 6.24 | Cash/sh | 7.78 | Dividend Yield | — |
| Payout | 0.00% | Employees | 224 | IPO | — |
| P/E | — | Forward P/E | -9.26 | PEG | — |
| P/S | — | P/B | 6.78 | P/C | — |
| EV/EBITDA | -8.48 | EV/Sales | — | Quick Ratio | 11.96 |
| Current Ratio | 12.21 | Debt/Eq | 19.36 | LT Debt/Eq | — |
| EPS (ttm) | -3.99 | EPS next Y | -4.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -38.12% |
| ROE | -73.25% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 70.99M |
| Shs Float | 49.55M | Short Float | 12.94% | Short Ratio | 7.33 |
| Short Interest | — | 52W High | 56.05 | 52W Low | 18.53 |
| Beta | 1.15 | Avg Volume | 1.35M | Volume | 304.78K |
| Target Price | $75.15 | Recom | Strong_buy | Prev Close | $42.37 |
| Price | $42.31 | Change | -0.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$75.15
Mean price target
2. Current target
$42.31
Latest analyst target
3. DCF / Fair value
$-32.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$42.31
Low
$33.00
High
$100.00
Mean
$75.15
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-19 | main | B of A Securities | Buy → Buy | $66 |
| 2025-12-19 | main | Goldman Sachs | Buy → Buy | $95 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $96 |
| 2025-12-11 | main | Wedbush | Neutral → Neutral | $33 |
| 2025-12-08 | main | Evercore ISI Group | Outperform → Outperform | $97 |
| 2025-12-05 | main | TD Cowen | Buy → Buy | $73 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $90 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $52 |
| 2025-10-16 | init | B of A Securities | — → Buy | $48 |
| 2025-08-07 | main | JP Morgan | Overweight → Overweight | $53 |
| 2025-08-04 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-06-02 | main | Scotiabank | Sector Outperform → Sector Outperform | $65 |
| 2025-06-02 | main | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-05-12 | main | Scotiabank | Sector Outperform → Sector Outperform | $55 |
| 2025-05-07 | main | Wedbush | Neutral → Neutral | $26 |
| 2025-05-07 | main | Cantor Fitzgerald | Overweight → Overweight | $100 |
| 2025-03-04 | main | JP Morgan | Overweight → Overweight | $71 |
| 2025-02-27 | main | Guggenheim | Buy → Buy | $61 |
| 2025-02-04 | init | Wolfe Research | — → Outperform | $49 |
| 2024-11-21 | init | Wells Fargo | — → Overweight | $70 |
- Late-stage biotech Vera Therapeutics heads to Boston and Miami - Stock Titan ue, 24 Feb 2026 13
- Assessing Vera Therapeutics (VERA) Valuation After Atacicept Phase 3 Success And Analyst Downgrade - simplywall.st Mon, 23 Feb 2026 00
- Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade) - Seeking Alpha Fri, 20 Feb 2026 21
- Why Vera Therapeutics Stock Rocked the Market on Tuesday - The Motley Fool ue, 02 Dec 2025 08
- Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment - Yahoo Finance hu, 19 Feb 2026 00
- Vera Bradley (NASDAQ:VRA) Stock Crosses Above 200 Day Moving Average - Here's Why - MarketBeat Fri, 20 Feb 2026 11
- Latham & Watkins Represents Vera Therapeutics in US$300 Million Offering of Common Stock - Latham & Watkins LLP Mon, 15 Dec 2025 08
- Vera Therapeutics, Inc. (VERA) Stock Analysis: A 71% Upside Potential In The Biotech Arena - DirectorsTalk Interviews ue, 10 Feb 2026 08
- Vera Therapeutics stock price target raised to $90 from $85 at H.C. Wainwright - Investing.com Mon, 10 Nov 2025 08
- Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire ue, 09 Dec 2025 08
- Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock at $42.50 per Share - Quiver Quantitative Wed, 10 Dec 2025 08
- Vera Therapeutics Stock Earns RS Rating Upgrade - Investor's Business Daily ue, 18 Nov 2025 08
- Why Vera Therapeutics Stock Crushed it Today - The Motley Fool Wed, 26 Nov 2025 08
- Two new Vera Therapeutics hires get stock options and 4-year RSUs - Stock Titan Fri, 06 Feb 2026 08
- Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns - Yahoo Finance Fri, 23 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | TURNER WILLIAM DONALD | Officer | — | 2026-02-04 00:00:00 | D |
| 1 | 68800 | — | — | Stock Award(Grant) at price 0.00 per share. | FORDYCE MARSHALL | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 2 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | YOUNG JOSEPH R | Officer | — | 2026-02-04 00:00:00 | D |
| 3 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | GRANT SEAN | Chief Financial Officer | — | 2026-02-04 00:00:00 | D |
| 4 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | BRENNER ROBERT | Officer | — | 2026-02-04 00:00:00 | D |
| 5 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | JOHNSON DAVID LEE | Chief Operating Officer | — | 2026-02-04 00:00:00 | D |
| 6 | 10000 | 155300 | — | Conversion of Exercise of derivative security at price 15.53 per share. | TURNER WILLIAM DONALD | Officer | — | 2025-12-15 00:00:00 | D |
| 7 | 10000 | 500767 | — | Sale at price 50.08 per share. | TURNER WILLIAM DONALD | Officer | — | 2025-12-15 00:00:00 | D |
| 8 | 5882 | 249985 | — | Purchase at price 42.50 per share. | ENRIGHT PATRICK G. | Director | — | 2025-12-11 00:00:00 | D |
| 9 | 10000 | 155300 | — | Conversion of Exercise of derivative security at price 15.53 per share. | TURNER WILLIAM DONALD | Officer | — | 2025-12-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -169.89K | 485.73K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -144.42M | -92.18M | -87.25M | -34.21M |
| TotalUnusualItems | -47.00K | -809.00K | 1.80M | |
| TotalUnusualItemsExcludingGoodwill | -47.00K | -809.00K | 1.80M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -152.15M | -95.99M | -89.06M | -32.61M |
| ReconciledDepreciation | 105.00K | 21.00K | -846.00K | 176.00K |
| EBITDA | -144.42M | -92.18M | -88.06M | -32.41M |
| EBIT | -144.52M | -92.20M | -88.06M | -32.59M |
| NetInterestIncome | 13.09M | 4.19M | 758.00K | -5.00K |
| InterestExpense | 7.63M | 3.79M | 992.00K | 20.00K |
| InterestIncome | 20.71M | 7.98M | 1.75M | 15.00K |
| NormalizedIncome | -152.15M | -95.99M | -88.42M | -33.92M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -152.15M | -95.99M | -89.06M | -32.61M |
| TotalExpenses | 167.17M | 102.01M | 90.90M | 34.40M |
| TotalOperatingIncomeAsReported | -167.17M | -102.01M | -90.90M | -34.40M |
| DilutedAverageShares | 55.33M | 42.71M | 26.57M | 13.44M |
| BasicAverageShares | 55.33M | 42.71M | 26.57M | 13.44M |
| DilutedEPS | -2.75 | -2.25 | -3.35 | -2.43 |
| BasicEPS | -2.75 | -2.25 | -3.35 | -2.43 |
| DilutedNIAvailtoComStockholders | -152.15M | -95.99M | -89.06M | -32.61M |
| NetIncomeCommonStockholders | -152.15M | -95.99M | -89.06M | -32.61M |
| NetIncome | -152.15M | -95.99M | -89.06M | -32.61M |
| NetIncomeIncludingNoncontrollingInterests | -152.15M | -95.99M | -89.06M | -32.61M |
| NetIncomeContinuousOperations | -152.15M | -95.99M | -89.06M | -32.61M |
| TaxProvision | 1.00K | 1.00K | 1.00K | 1.00K |
| PretaxIncome | -152.15M | -95.99M | -89.06M | -32.61M |
| OtherIncomeExpense | 1.94M | 1.83M | 1.09M | 1.80M |
| OtherNonOperatingIncomeExpenses | 1.94M | 1.83M | 1.90M | |
| SpecialIncomeCharges | 0.00 | 2.69M | ||
| GainOnSaleOfBusiness | 0.00 | 2.69M | ||
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | -47.00K | -809.00K | -892.00K | |
| NetNonOperatingInterestIncomeExpense | 13.09M | 4.19M | 758.00K | -5.00K |
| InterestExpenseNonOperating | 7.63M | 3.79M | 992.00K | 20.00K |
| InterestIncomeNonOperating | 20.71M | 7.98M | 1.75M | 15.00K |
| OperatingIncome | -167.17M | -102.01M | -90.90M | -34.40M |
| OperatingExpense | 167.17M | 102.01M | 90.90M | 34.40M |
| ResearchAndDevelopment | 126.17M | 78.22M | 68.99M | 22.48M |
| SellingGeneralAndAdministration | 41.00M | 23.79M | 21.91M | 11.92M |
| GeneralAndAdministrativeExpense | 41.00M | 23.79M | 21.91M | 11.92M |
| OtherGandA | 41.00M | 23.79M | 21.91M | 11.92M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 63.56M | 44.45M | 27.80M | 21.28M |
| ShareIssued | 63.56M | 44.45M | 27.80M | 21.28M |
| NetDebt | 4.20M | |||
| TotalDebt | 54.64M | 53.71M | 31.29M | 4.92M |
| TangibleBookValue | 577.15M | 101.69M | 76.91M | 69.59M |
| InvestedCapital | 627.84M | 151.56M | 101.72M | 74.52M |
| WorkingCapital | 625.85M | 149.72M | 100.10M | 74.85M |
| NetTangibleAssets | 577.15M | 101.69M | 76.91M | 69.59M |
| CapitalLeaseObligations | 3.95M | 3.83M | 6.48M | 0.00 |
| CommonStockEquity | 577.15M | 101.69M | 76.91M | 69.59M |
| TotalCapitalization | 627.84M | 151.56M | 101.72M | 74.52M |
| TotalEquityGrossMinorityInterest | 577.15M | 101.69M | 76.91M | 69.59M |
| StockholdersEquity | 577.15M | 101.69M | 76.91M | 69.59M |
| GainsLossesNotAffectingRetainedEarnings | 393.00K | 251.00K | -224.00K | 0.00 |
| OtherEquityAdjustments | 393.00K | 251.00K | -224.00K | |
| RetainedEarnings | -461.25M | -309.10M | -213.11M | -124.06M |
| AdditionalPaidInCapital | 1.04B | 410.49M | 290.22M | 193.63M |
| CapitalStock | 64.00K | 44.00K | 28.00K | 21.00K |
| CommonStock | 64.00K | 44.00K | 28.00K | 21.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 78.53M | 73.86M | 54.53M | 14.16M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 53.16M | 51.56M | 28.93M | 6.47M |
| OtherNonCurrentLiabilities | 1.26M | |||
| NonCurrentAccruedExpenses | 0.00 | 286.00K | 286.00K | 286.00K |
| LongTermDebtAndCapitalLeaseObligation | 53.16M | 51.27M | 28.64M | 4.92M |
| LongTermCapitalLeaseObligation | 2.47M | 1.40M | 3.83M | 0.00 |
| LongTermDebt | 50.69M | 49.88M | 24.81M | 4.92M |
| CurrentLiabilities | 25.37M | 22.30M | 25.60M | 7.69M |
| OtherCurrentLiabilities | 377.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 1.48M | 2.44M | 2.65M | |
| CurrentCapitalLeaseObligation | 1.48M | 2.44M | 2.65M | 0.00 |
| PayablesAndAccruedExpenses | 23.89M | 19.87M | 22.95M | 7.31M |
| CurrentAccruedExpenses | 16.01M | 6.82M | 8.18M | 4.91M |
| Payables | 7.88M | 13.04M | 14.77M | 2.41M |
| DuetoRelatedPartiesCurrent | 217.00K | 1.93M | 2.78M | 1.02M |
| AccountsPayable | 7.67M | 11.12M | 11.99M | 1.39M |
| TotalAssets | 655.68M | 175.55M | 131.44M | 83.75M |
| TotalNonCurrentAssets | 4.46M | 3.52M | 5.74M | 1.21M |
| OtherNonCurrentAssets | 131.00K | 482.00K | 513.00K | 344.00K |
| NonCurrentPrepaidAssets | 51.00K | |||
| InvestmentsAndAdvances | 58.00K | 867.00K | ||
| InvestmentinFinancialAssets | 58.00K | 867.00K | ||
| AvailableForSaleSecurities | 58.00K | 867.00K | ||
| NetPPE | 4.33M | 3.04M | 5.22M | 0.00 |
| GrossPPE | 4.33M | 3.04M | 5.22M | 0.00 |
| OtherProperties | 960.00K | 92.00K | 51.00K | |
| BuildingsAndImprovements | 3.37M | 2.95M | 5.17M | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 651.22M | 172.02M | 125.70M | 82.54M |
| OtherCurrentAssets | 913.00K | 2.24M | 719.00K | 480.00K |
| PrepaidAssets | 5.68M | 8.56M | 10.33M | 2.38M |
| Receivables | 3.77M | 512.00K | ||
| AccruedInterestReceivable | 3.77M | 512.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 640.85M | 160.72M | 114.65M | 79.67M |
| OtherShortTermInvestments | 548.21M | 115.03M | 71.19M | 0.00 |
| CashAndCashEquivalents | 92.65M | 45.68M | 43.46M | 79.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -135.65M | -92.24M | -67.66M | -23.71M |
| RepurchaseOfCapitalStock | -13.00K | 0.00 | ||
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | 24.74M | 19.82M | 4.92M |
| IssuanceOfCapitalStock | 632.54M | 115.00M | 86.13M | 51.18M |
| CapitalExpenditure | -972.00K | -63.00K | -62.00K | |
| InterestPaidSupplementalData | 6.65M | 3.35M | 895.00K | 17.00K |
| EndCashPosition | 92.65M | 45.68M | 43.75M | 79.97M |
| BeginningCashPosition | 45.68M | 43.75M | 79.97M | 54.00M |
| ChangesInCash | 46.97M | 1.93M | -36.22M | 25.97M |
| FinancingCashFlow | 606.67M | 133.54M | 101.93M | 53.88M |
| CashFlowFromContinuingFinancingActivities | 606.67M | 133.54M | 101.93M | 53.88M |
| NetOtherFinancingCharges | -39.26M | -7.26M | -6.10M | -2.77M |
| ProceedsFromStockOptionExercised | 13.41M | 1.06M | 2.08M | 550.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 632.52M | 115.00M | 86.13M | 51.18M |
| CommonStockPayments | -13.00K | 0.00 | ||
| CommonStockIssuance | 632.54M | 115.00M | 86.13M | 51.18M |
| NetIssuancePaymentsOfDebt | 0.00 | 24.74M | 19.82M | 4.92M |
| NetLongTermDebtIssuance | 0.00 | 24.74M | 19.82M | 4.92M |
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | 24.74M | 19.82M | 4.92M |
| InvestingCashFlow | -425.03M | -39.43M | -70.55M | -4.20M |
| CashFlowFromContinuingInvestingActivities | -425.03M | -39.43M | -70.55M | -4.20M |
| NetOtherInvestingChanges | -5.00M | |||
| NetInvestmentPurchaseAndSale | -424.06M | -39.37M | -70.49M | 0.00 |
| SaleOfInvestment | 278.96M | 185.56M | 78.00M | 0.00 |
| PurchaseOfInvestment | -703.01M | -224.93M | -148.49M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 796.00K | ||
| SaleOfIntangibles | 0.00 | 796.00K | ||
| NetPPEPurchaseAndSale | -972.00K | -63.00K | -62.00K | 0.00 |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -972.00K | -63.00K | -62.00K | 0.00 |
| OperatingCashFlow | -134.68M | -92.18M | -67.60M | -23.71M |
| CashFlowFromContinuingOperatingActivities | -134.68M | -92.18M | -67.60M | -23.71M |
| ChangeInWorkingCapital | 2.66M | -5.82M | 6.75M | 3.51M |
| ChangeInOtherCurrentLiabilities | -2.41M | -2.65M | -2.60M | 0.00 |
| ChangeInOtherCurrentAssets | 351.00K | -262.00K | -111.00K | -51.00K |
| ChangeInPayablesAndAccruedExpense | 3.73M | -3.09M | 17.64M | 5.87M |
| ChangeInAccruedExpense | 7.19M | -2.21M | 7.04M | 5.39M |
| ChangeInPayable | -3.45M | -873.00K | 10.61M | 475.00K |
| ChangeInAccountPayable | -3.45M | -873.00K | 10.61M | 475.00K |
| ChangeInPrepaidAssets | 981.00K | 173.00K | -8.18M | -2.31M |
| OtherNonCashItems | 2.87M | 2.55M | 5.86M | 4.00M |
| StockBasedCompensation | 20.80M | 11.49M | 8.89M | 3.01M |
| UnrealizedGainLossOnInvestmentSecurities | 47.00K | 809.00K | 892.00K | |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -8.97M | -4.43M | ||
| DepreciationAmortizationDepletion | 105.00K | 21.00K | -846.00K | 176.00K |
| DepreciationAndAmortization | 105.00K | 21.00K | -846.00K | 176.00K |
| Depreciation | -4.09M | -846.00K | 176.00K | |
| OperatingGainsLosses | -2.69M | |||
| GainLossOnSaleOfPPE | 0.00 | -2.69M | ||
| NetIncomeFromContinuingOperations | -152.15M | -95.99M | -89.06M | -32.61M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VERA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|